申请人:QILU REGOR THERAPEUTICS INC.
公开号:US20220024901A1
公开(公告)日:2022-01-27
Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.